NFKB1 and COVID-19: In summary, our transcriptomic findings show that dexamethasone corrects some of the pathways that are altered in severe COVID-19 as compared to mild patients, namely it reduces immune exhaustion, type III interferon and NF-κB signaling, while restoring virus-host interactions.